Merck on Tuesday issued full-year 2025 revenue guidance that fell short of Wall Street's expectations. The company said that sales range reflects a decision to halt shipments of Gardasil, a ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

As of 10:19:56 AM EDT. Market Open. Merck (NYSE:MRK) experienced a 13% increase in its stock price over the last month, aided by several significant developments. The company's upcoming ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other cheap high dividend stocks. According to Deutsche Bank Wealth Management, the global ...

SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Merck & Co., Inc. (NYSE: MRK) securities between February 3, 2022 and February 3, 2025 ...

In what’s shaping up to be a red-letter week for Gardasil, Merck & Co. has simultaneously opened a massive new manufacturing facility for the human papillomavirus (HPV) shot in the U.S. and put ...

Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, the latest drugmaker to boost its U.S. manufacturing amid President Donald Trump's tariff threats. Trump ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with ...

(1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...